Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

AIM: To determine the effect of combined serelaxin and rosiglitazone treatment on established hepatic fibrosis. METHODS: Hepatic fibrosis was induced in mice by carbon tetrachloride administration for 6 wk, or vehicle alone (nonfibrotic mice). For the final 2 wk, mice were treated with rosiglitazone...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Robert G, Simpson, Ronda L, Hamel, Frederick G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473119/
https://www.ncbi.nlm.nih.gov/pubmed/28652653
http://dx.doi.org/10.3748/wjg.v23.i22.3999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473119/
https://www.ncbi.nlm.nih.gov/pubmed/28652653
http://dx.doi.org/10.3748/wjg.v23.i22.3999

Ejemplares similares